Pembrolizumab and chemotherapy with or without radiotherapy as an adjuvant therapy for treating newly diagnosed high-risk endometrial cancer

Pembrolizumab in combination with chemotherapy with or without radiotherapy is currently in clinical development for the treatment of newly diagnosed high-risk endometrial cancer after surgery (adjuvant therapy). Endometrial cancer is the most common form of womb cancer and originates from the lining of the womb (endometrium). The most common symptoms of this cancer are post-menopausal or irregular vaginal bleeding. Women with high-risk endometrial cancer are at increased risk of recurrence and disease progression following surgery. Current adjuvant therapy options include chemotherapy and/or radiotherapy, but there is a need for additional treatment options to improve outcomes. There are currently few targeted treatments available for this patient population.